With regard to clinical significance, TMPRSS3 acts as a pro-oncogene in breast cancer [33, 34], pancreatic cancer [35], glioma [36], gastric cancer [37], and nasopharyngeal cancer [38]. This evidence concerns the gene TMPRSS3 and familial pancreatic carcinoma.